Published in Eur J Pharmacol on September 16, 2006
Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation. J Cell Sci (2007) 1.00
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PLoS One (2014) 0.91
Differential regulation of HIF-mediated pathways increases mitochondrial metabolism and ATP production in hypoxic osteoclasts. J Pathol (2013) 0.91
Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. BMC Musculoskelet Disord (2010) 0.83
Developments in the synovial biology field 2006. Arthritis Res Ther (2007) 0.82
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol (2015) 0.80
Hypoxic regulation of osteoclast differentiation and bone resorption activity. Hypoxia (Auckl) (2015) 0.76
Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. PLoS One (2015) 0.75
Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ. PLoS One (2016) 0.75
Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine (2003) 1.59
Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol (2014) 1.51
The role of the calcium-sensing receptor in the development and progression of cancer. Endocr Rev (2009) 1.23
Calcium sensing receptor signalling in physiology and cancer. Biochim Biophys Acta (2012) 1.19
Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol (2004) 1.16
The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem (2008) 1.14
Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res (2009) 1.10
High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol (2008) 1.09
Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology (2005) 1.08
Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol (2003) 1.08
Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. Circulation (2008) 1.01
Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor. Exp Cell Res (2009) 1.00
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis (2008) 0.99
Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem (2004) 0.99
Agonists and allosteric modulators of the calcium-sensing receptor and their therapeutic applications. Mol Pharmacol (2009) 0.97
Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation. Cell Physiol Biochem (2009) 0.96
Indoxyl sulphate inhibits osteoclast differentiation and function. Nephrol Dial Transplant (2011) 0.95
The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant (2010) 0.94
Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. Cardiovasc Res (2013) 0.93
Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab (2003) 0.91
Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. Mol Cell Endocrinol (2010) 0.88
Strontium ranelate decreases receptor activator of nuclear factor-ΚB ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor. Mol Pharmacol (2010) 0.88
In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts. Cancer Chemother Pharmacol (2003) 0.87
Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiency. PLoS One (2009) 0.87
Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant (2003) 0.86
The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K. Biomaterials (2007) 0.86
Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. Free Radic Biol Med (2005) 0.86
Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy. J Clin Endocrinol Metab (2014) 0.86
Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochem Pharmacol (2006) 0.85
Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet (2002) 0.83
An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. BMC Med Genomics (2012) 0.83
Bone mineral density directly correlates with elevated serum leptin in haemodialysis patients. Nephrol Dial Transplant (2003) 0.81
Total calcium-sensing receptor expression in circulating monocytes is increased in rheumatoid arthritis patients with severe coronary artery calcification. Arthritis Res Ther (2014) 0.81
Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. Ther Apher Dial (2011) 0.81
Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. Apoptosis (2006) 0.80
Enzymatically-tailored pectins differentially influence the morphology, adhesion, cell cycle progression and survival of fibroblasts. Biochim Biophys Acta (2008) 0.80
Genetic heterogeneity versus molecular analysis of prion susceptibility in neuroblasma N2a sublines. Arch Virol (2008) 0.80
Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy -- a pilot study from the VErA cohort. Joint Bone Spine (2012) 0.80
Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. J Cell Physiol (2009) 0.80
[Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease]. Nephrol Ther (2011) 0.79
Potential anti-catabolic and anabolic properties of strontium ranelate. Curr Mol Pharmacol (2012) 0.79
Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract (2010) 0.79
Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. Arthritis Care Res (Hoboken) (2010) 0.78
Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. Leuk Res (2008) 0.78
Wilms' tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas. Eur J Hum Genet (2012) 0.78
Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D (2013) 0.78
Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations. PLoS One (2012) 0.78
Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification . Circ J (2014) 0.77
Determination and modulation of total and surface calcium-sensing receptor expression in monocytes in vivo and in vitro. PLoS One (2013) 0.77
Breast cancer cell line MDA-MB 231 exerts a potent and direct anti-apoptotic effect on mature osteoclasts. Biochem Biophys Res Commun (2004) 0.77
Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. Bone (2009) 0.77
Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease. J Nephrol (2010) 0.77
Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med (2012) 0.76
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Ann Hematol (2004) 0.76
Calcitriol prevents in vitro vascular smooth muscle cell mineralization by regulating calcium-sensing receptor expression. Endocrinology (2015) 0.76
Erratum: Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol (2015) 0.75
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant (2017) 0.75
Cutaneous epidermal cysts as a presentation of gorlin syndrome. Arch Dermatol (2009) 0.75
Ventriculo-Arterial Coupling Analysis Predicts the Hemodynamic Response to Norepinephrine in Hypotensive Postoperative Patients: A Prospective Observational Study. Crit Care Med (2017) 0.75
Prognostic implications of plasma myoglobin levels in patients with chronic kidney disease. Int J Artif Organs (2012) 0.75
[Partnership between academic research and industry to study a new anti-osteoporotic drug]. Med Sci (Paris) (2005) 0.75
Oligogalacturonic acid inhibit bone resorption and collagen degradation through its interaction with type I collagen. Biochem Pharmacol (2009) 0.75